Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to elevate them to “priority asset ...

Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study. The eye health company had been evaluating the alpha-2B agonist, dubbed BL1107, in a mid-stage ...

The Advanced Research Projects Agency for Health (ARPA-H) has awarded a new tranche of funds for companies and institutions ...

Roche has halted development on two of its Huntington’s disease prospects, delivering another blow to a patient community that has long awaited new medicines. The Swiss drugmaker explained its ...

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech ...

Fate Therapeutics has seen improvements in 4 patients with treatment-resistant systemic sclerosis who were dosed with it | ...

GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both drugs ...

Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...

The merged entity will retain the Scipher brand and take advantage of Chemomab’s Nasdaq listing, although the ticker will ...

Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy (DMD) drug candidate is active in adults, ...

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...